Project 2 of the Johns Hopkins Alzheimer's Disease Research Center (ADRC) is titled """"""""Modeling an anti-amyloid therapy for AD: potential for cognitive recovery"""""""". This project focuses the role of oligomeric amyloid-beta (A-beta) peptides in the cognitive impairment associated with Alzheimer's disease (AD). The project will test the hypothesis that accumulation of oligomeric A-beta species impairs learning and memory and that these cognitive impairments can be reversed with suppression of A-beta generation. To address this question we will use a mouse model of A-beta amyloidosis in which the expression of mutant amyloid precursor protein (APP) is controlled by a tetracycline-regulated promoter (these transgenic mice are known as TetOffAPP mice). A-beta production can be suppressed in these mice with doxycycline. Preliminary data suggest that following A-beta suppression with doxycycline, amyloid deposits are stable but there is, nevertheless, a gradual amelioration of the memory deficits. This finding has led to the following three specific aims: (1) Aim 1: To determine whether the reduction of oligomoeric A-beta species derived from newly-synthesized A-beta peptides improves learning and memory in the conditional TetOffAPP mouse models after genetically induced arrest of APP expression and new A-beta production. (2) Aim 2: To determine whether recovery of synaptic damage is associated with cognitive improvement after A-beta production - synaptic, glutamatergic and immediate early gene markers of neuronal activity will be assessed in mice with significant amelioration of memory deficits. (3) Aim 3: To examine the role of neurodegenerative changes in CNS monoamine systems in relation to the degree of cognitive recovery observed after reduction of A-beta peptides in the TetOffAPP mice. Collectively, outcomes from these studies will address an important issue regarding the value of an anti-amyloid therapeutic strategy for AD by assessing the magnitude of functional repair and recovery after synaptic damage by oligomeric A-beta. Evaluation of outcomes of therapeutic interventions that target A-beta production will inform appropriate expectations in clinical trials.

Public Health Relevance

Understanding mechanisms that influence the pathology of Alzheimer's disease, and whether it is possible to reduce pathology once it has developed, is of crucial importance in developing strategies to combat Alzheimer's disease, a neurodegenerative disorder which affects over 6 million Americans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-30
Application #
8448154
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
30
Fiscal Year
2013
Total Cost
$208,914
Indirect Cost
$81,527
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Na, Chan Hyun; Barbhuiya, Mustafa A; Kim, Min-Sik et al. (2018) Discovery of noncanonical translation initiation sites through mass spectrometric analysis of protein N termini. Genome Res 28:25-36
Eftekharzadeh, Bahareh; Daigle, J Gavin; Kapinos, Larisa E et al. (2018) Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron 99:925-940.e7
Kaji, Seiji; Maki, Takakuni; Kinoshita, Hisanori et al. (2018) Pathological Endogenous ?-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. Stem Cell Reports 10:356-365
Johnson, Erik C B; Dammer, Eric B; Duong, Duc M et al. (2018) Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13:52
Albert, Marilyn; Zhu, Yuxin; Moghekar, Abhay et al. (2018) Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain :
Oh, Esther S; Blennow, Kaj; Bigelow, George E et al. (2018) Abnormal CSF amyloid-?42 and tau levels in hip fracture patients without dementia. PLoS One 13:e0204695
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Ganguli, Mary; Albanese, Emiliano; Seshadri, Sudha et al. (2018) Population Neuroscience: Dementia Epidemiology Serving Precision Medicine and Population Health. Alzheimer Dis Assoc Disord 32:1-9
Tsapkini, Kyrana; Webster, Kimberly T; Ficek, Bronte N et al. (2018) Electrical brain stimulation in different variants of primary progressive aphasia: A randomized clinical trial. Alzheimers Dement (N Y) 4:461-472
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739

Showing the most recent 10 out of 830 publications